Tag: TAZVERIK

Ipsen to acquire American biopharma company Epizyme for $247m

pallavi123- June 27, 2022

French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed ... Read More

Roche gets FDA nod for cobas EZH2 Mutation Test as companion diagnostic for follicular lymphoma patients

pharmanewsdaily- June 20, 2020

Roche has secured approval from the US Food and Drug Administration (FDA) for its cobas EZH2 Mutation Test as a companion diagnostic for TAZVERIK (tazemetostat), ... Read More

Epizyme gets FDA priority review for TAZVERIK in follicular lymphoma

pharmanewsdaily- February 17, 2020

Epizyme has been granted priority review by the US Food and Drug Administration (FDA) for the use of TAZVERIK (tazemetostat) in relapsed or refractory follicular ... Read More